About - DHR :

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization; microscopes; genomics consumables; and Gene and Cell Therapy. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology, molecular, acute care, and pathology diagnostics products. This segment offers clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

Employees - 61000, CEO - Mr. Rainer M. Blair, Sector - Healthcare, Country - US, Market Cap - 141.59B

Altman ZScore(max is 10): 4.44, Piotroski Score(max is 10): 7, Working Capital: $2699000000, Total Assets: $77542000000, Retained Earnings: $44188000000, EBIT: 4995000000, Total Liabilities: $27992000000, Revenue: $23875000000

AryaFin Target Price - $193.06 - Current Price $197.90 - Analyst Target Price $264.13

Stats & Key Metrics
TickerDHR
IndexS&P 500
Curent Price 197.90
Change-3.54%
Market Cap141.59B
Average Volume4.35M
Income3.90B
Sales23.88B
Book Value/Share68.90
Cash/Share2.90
Dividend Est1.21 (0.61%)
Dividend TTM1.13 (0.57%)
Dividend Ex-DateMar 28, 2025
Employees63000
Moving Avg 20days-4.86%
Moving Avg 50days-6.69%
Moving Avg 200days-18.64%
Shares Outstanding719.10M
Earnings DateApr 22 BMO
Inst. Ownership81.36%
Key Ratios & Margins
Price/Earnings37.43
Forwad P/E23.03
PE Growth4.46
Price/Sales5.93
Price/Book2.87
Price/Cash68.14
Price/FCF26.73
Quick Ratio1.05
Current Ratio1.40
Debt/Equity0.35
Return on Assets4.81%
Return on Equity7.57%
Return on Investment5.91%
Gross Margin59.50%
Ops Margin21.71%
Profit Margin16.33%
RSI34.87
BETA(β)0.80
From 52week Low0.56%
From 52week High-29.75%
Earnings & Valuation
EPS5.29
EPS next Year8.59
EPS next Qtr1.62
EPS this Year2.24%
EPS next 5 Year8.39%
EPS past 5 Year9.03%
Sales past 5 Year7.33%
EPS Y/Y-17.25%
Sales Y/Y-13.50%
EPS Q/Q3.13%
Sales Q/Q2.08%
Sales Surprise1.44%
EPS Surprise-0.81%
ATR(14)5.28
Perf Week-5.81%
Perf Month-6.01%
Perf Quarter-13.79%
Perf Year-19.53%
Perf YTD-13.79%
Target Price264.13

AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer